

**Supplementary Table 1.** The Reason for Discontinuation of Tofacitinib Treatment (n = 21)

	No. (%)
Primary failure	15 (71.4)
Partial response	3 (14.2)
Loss of response	2 (9.5)
Adverse events	1 (4.8)
Others	0